200 related articles for article (PubMed ID: 33073036)
1. Performance of a Three-Tier (IRT-DNA-IRT) Cystic Fibrosis Screening Algorithm in British Columbia.
Sinclair G; McMahon V; Schellenberg A; Nelson TN; Chilvers M; Vallance H
Int J Neonatal Screen; 2020 Jun; 6(2):46. PubMed ID: 33073036
[TBL] [Abstract][Full Text] [Related]
2. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
[TBL] [Abstract][Full Text] [Related]
3. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years.
Skov M; Baekvad-Hansen M; Hougaard DM; Skogstrand K; Lund AM; Pressler T; Olesen HV; Duno M
Pediatr Pulmonol; 2020 Feb; 55(2):549-555. PubMed ID: 31682332
[TBL] [Abstract][Full Text] [Related]
4. Immunoreactive trypsinogen levels in newborn screened infants with an inconclusive diagnosis of cystic fibrosis.
Ooi CY; Sutherland R; Castellani C; Keenan K; Boland M; Reisman J; Bjornson C; Chilvers MA; van Wylick R; Kent S; Price A; Mateos-Corral D; Hughes D; Solomon M; Zuberbuhler P; Brusky J; Durie PR; Ratjen F; Gonska T
BMC Pediatr; 2019 Oct; 19(1):369. PubMed ID: 31640630
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of children with cystic fibrosis screen positive, inconclusive diagnosis/CFTR related metabolic syndrome.
Gunnett MA; Baker E; Mims C; Self ST; Gutierrez HH; Guimbellot JS
Front Pediatr; 2023; 11():1127659. PubMed ID: 36969284
[TBL] [Abstract][Full Text] [Related]
6. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.
Corbetta C; Seia M; Bassotti A; Ambrosioni A; Giunta A; Padoan R
J Med Screen; 2002; 9(2):60-3. PubMed ID: 12133923
[TBL] [Abstract][Full Text] [Related]
7. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols.
Gregg RG; Wilfond BS; Farrell PM; Laxova A; Hassemer D; Mischler EH
Am J Hum Genet; 1993 Mar; 52(3):616-26. PubMed ID: 7680526
[TBL] [Abstract][Full Text] [Related]
8. Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods.
Gregg RG; Simantel A; Farrell PM; Koscik R; Kosorok MR; Laxova A; Laessig R; Hoffman G; Hassemer D; Mischler EH; Splaingard M
Pediatrics; 1997 Jun; 99(6):819-24. PubMed ID: 9164776
[TBL] [Abstract][Full Text] [Related]
9. A survey of newborn screening for cystic fibrosis in Europe.
Southern KW; Munck A; Pollitt R; Travert G; Zanolla L; Dankert-Roelse J; Castellani C;
J Cyst Fibros; 2007 Jan; 6(1):57-65. PubMed ID: 16870510
[TBL] [Abstract][Full Text] [Related]
10. Cystic fibrosis newborn screening: the importance of bloodspot sample quality.
Doull I; Course CW; Hanks RE; Southern KW; Forton JT; Thia LP; Moat SJ
Arch Dis Child; 2021 Mar; 106(3):253-257. PubMed ID: 32859613
[TBL] [Abstract][Full Text] [Related]
11. Immunoreactive Trypsinogen in Infants Born to Women with Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor.
Patel P; Yeley J; Brown C; Wesson M; Lesko BG; Slaven JE; Chmiel JF; Jain R; Sanders DB
Int J Neonatal Screen; 2023 Feb; 9(1):. PubMed ID: 36975847
[TBL] [Abstract][Full Text] [Related]
12. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population.
Sommerburg O; Lindner M; Muckenthaler M; Kohlmueller D; Leible S; Feneberg R; Kulozik AE; Mall MA; Hoffmann GF
J Inherit Metab Dis; 2010 Oct; 33(Suppl 2):S263-71. PubMed ID: 20714932
[TBL] [Abstract][Full Text] [Related]
13. A survey of the prevalence, management and outcome of infants with an inconclusive diagnosis following newborn bloodspot screening for cystic fibrosis (CRMS/CFSPID) in six Italian centres.
Terlizzi V; Claut L; Tosco A; Colombo C; Raia V; Fabrizzi B; Lucarelli M; Angeloni A; Cimino G; Castaldo A; Marsiglio L; Timpano S; Cirilli N; Moroni L; Festini F; Piccinini P; Zavataro L; Bonomi P; Taccetti G; Southern KW; Padoan R
J Cyst Fibros; 2021 Sep; 20(5):828-834. PubMed ID: 33883100
[TBL] [Abstract][Full Text] [Related]
14. Immunoreactive trypsinogen in healthy newborns and infants with cystic fibrosis.
Fingerhut R; Rueegg CS; Imahorn O; Pedersen ESL; Kuehni CE; Gallati S; Regamey N; Barben J
Arch Dis Child Fetal Neonatal Ed; 2023 Mar; 108(2):176-181. PubMed ID: 36351789
[TBL] [Abstract][Full Text] [Related]
15. Lessons learned from 20 years of newborn screening for cystic fibrosis.
Massie RJ; Curnow L; Glazner J; Armstrong DS; Francis I
Med J Aust; 2012 Jan; 196(1):67-70. PubMed ID: 22256939
[TBL] [Abstract][Full Text] [Related]
16. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
Sontag MK; Hammond KB; Zielenski J; Wagener JS; Accurso FJ
J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
[TBL] [Abstract][Full Text] [Related]
17. False negatives in the newborn screening for cystic fibrosis in Western Andalusia: Results from a 10-year experience.
Escudero-Ávila R; Delgado-Pecellín C; Moreno-Valera MJ; Carrasco-Hernández L; Quintana-Gallego ME; Delgado-Pecellín I
Pediatr Pulmonol; 2023 Sep; 58(9):2464-2468. PubMed ID: 36196044
[TBL] [Abstract][Full Text] [Related]
18. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
[TBL] [Abstract][Full Text] [Related]
19. Screening for cystic fibrosis in New York State: considerations for algorithm improvements.
Kay DM; Maloney B; Hamel R; Pearce M; DeMartino L; McMahon R; McGrath E; Krein L; Vogel B; Saavedra-Matiz CA; Caggana M; Tavakoli NP
Eur J Pediatr; 2016 Feb; 175(2):181-93. PubMed ID: 26293390
[TBL] [Abstract][Full Text] [Related]
20. Cystic fibrosis screen positive inconclusive diagnosis (CFSPID): Experience in Tuscany, Italy.
Terlizzi V; Mergni G; Buzzetti R; Centrone C; Zavataro L; Braggion C
J Cyst Fibros; 2019 Jul; 18(4):484-490. PubMed ID: 31005549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
